当前位置: 首页 >> 检索结果
4581. Comparison of high-dose with low-dose aspirin in patients with mechanical heart valve replacement treated with oral anticoagulant.
There are no reported studies on the safety and efficacy of low-dose aspirin with low-intensity oral anticoagulation in patients with heart valve replacement. In this study, we compared the use of 100 mg/d aspirin with 650 mg/d aspirin in the prevention of systemic embolism and vascular death in patients with heart valve replacement who were being treated with oral anticoagulants with a target international normalized ratio (INR) of 2.0 to 3.0.
4582. AREVA: multicenter randomized comparison of low-dose versus standard-dose anticoagulation in patients with mechanical prosthetic heart valves.
作者: J Acar.;B Iung.;J P Boissel.;M M Samama.;P L Michel.;J P Teppe.;J C Pony.;H L Breton.;D Thomas.;R Isnard.;G de Gevigney.;E Viguier.;A Sfihi.;G Hanania.;M Ghannem.;A Mirode.;C Nemoz.
来源: Circulation. 1996年94卷9期2107-12页
Moderate anticoagulation may be proposed to reduce the risk of hemorrhage for certain patients with a mechanical prosthesis, but the consequences for risk of thromboembolism are debated.
4583. Effects of integrelin, a platelet glycoprotein IIb/IIIa receptor antagonist, in unstable angina. A randomized multicenter trial.
作者: S P Schulman.;P J Goldschmidt-Clermont.;E J Topol.;R M Califf.;F I Navetta.;J T Willerson.;N C Chandra.;A D Guerci.;J J Ferguson.;R A Harrington.;A M Lincoff.;S J Yakubov.;P F Bray.;R D Bahr.;C L Wolfe.;P G Yock.;H V Anderson.;T W Nygaard.;S J Mason.;M B Effron.;A Fatterpacker.;S Raskin.;J Smith.;L Brashears.;P Gottdiener.;C du Mee.;M M Kitt.;G Gerstenblith.
来源: Circulation. 1996年94卷9期2083-9页
Although aspirin is beneficial in patients with unstable angina, it is a relatively weak inhibitor of platelet aggregation. The effect of Integrelin, which inhibits the platelet fibrinogen receptor glycoprotein (GP) IIb/IIIa, on the frequency and duration of Holter ischemia was evaluated in 227 patients with unstable angina.
4584. Comparable potent coronary constrictor effects of endothelin-1 and big endothelin-1 in humans.
Endothelin-1 (ET-1) is a potent vasoconstrictor produced from the precursor big ET-1 in endothelial cells. The coronary effects of these peptides in humans in vivo are unknown. Therefore, the effects of ET-1 and big ET-1 on coronary blood flow in relation to plasma ET-1 and big ET-1 levels were compared in healthy subjects.
4585. Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. ECAT Study Group. European Concerted Action on Thrombosis and Disabilities.
作者: I Juhan-Vague.;S D Pyke.;M C Alessi.;J Jespersen.;F Haverkate.;S G Thompson.
来源: Circulation. 1996年94卷9期2057-63页
Disturbances of the fibrinolytic system that lead to decreased removal of fibrin deposits may be important risk factors for coronary thrombosis. There is as yet no consensus on the prognostic value of fibrinolytic parameters, which may be attributed in part to the choice of confounding variables controlled for.
4586. The Asp9 Asn mutation in the lipoprotein lipase gene is associated with increased progression of coronary atherosclerosis. REGRESS Study Group, Interuniversity Cardiology Institute, Utrecht, The Netherlands. Regression Growth Evaluation Statin Study.
作者: J W Jukema.;A J van Boven.;B Groenemeijer.;A H Zwinderman.;J H Reiber.;A V Bruschke.;J A Henneman.;G P Molhoek.;T Bruin.;H Jansen.;E Gagné.;M R Hayden.;J J Kastelein.
来源: Circulation. 1996年94卷8期1913-8页
Many patients suffering from premature coronary artery disease report a family history for such events. A mutation in a particular gene, which confers susceptibility for atherosclerosis, will be found more frequently in individuals suffering from coronary atherosclerosis than in the general population. We have recently reported the identification of an Asp9 Asn substitution in the lipoprotein lipase (LPL) enzyme. We analyzed the impact of this mutation on the progression of coronary atherosclerosis and the effect of pravastatin in both carriers and noncarriers.
4587. Radiofrequency catheter ablation of right ventricular tachycardia late after repair of congenital heart defects.
Ventricular arrhythmias after repair of congenital heart defects are a common finding and possibly contribute to sudden death in these patients. Optimal antiarrhythmic management has not yet been defined.
4588. Reconstruction of brachial artery pressure from noninvasive finger pressure measurements.
作者: W J Bos.;J van Goudoever.;G A van Montfrans.;A H van den Meiracker.;K H Wesseling.
来源: Circulation. 1996年94卷8期1870-5页
Pulse wave distortions, mainly caused by reflections, and pressure gradients, caused by flow in the resistive vascular tree, may cause differences between finger and brachial artery pressures. These differences may limit the use of finger pressure measurements. We investigated whether brachial artery pressure waves could be reconstructed from finger pressure measurements by correcting for the pressure gradient in addition to correction for pulse wave distortion with a previously described filter.
4589. Age and outcome with contemporary thrombolytic therapy. Results from the GUSTO-I trial. Global Utilization of Streptokinase and TPA for Occluded coronary arteries trial.
作者: H D White.;G I Barbash.;R M Califf.;R J Simes.;C B Granger.;W D Weaver.;N S Kleiman.;P E Aylward.;J M Gore.;A Vahanian.;K L Lee.;A M Ross.;E J Topol.
来源: Circulation. 1996年94卷8期1826-33页
Elderly patients with acute myocardial infarction have much to gain from reperfusion with thrombolytic therapy but are also at increased risk of adverse events. We examined outcomes according to age of patients receiving thrombolysis in an international trial.
4590. Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation. Ibutilide Repeat Dose Study Investigators.
作者: B S Stambler.;M A Wood.;K A Ellenbogen.;K T Perry.;L K Wakefield.;J T VanderLugt.
来源: Circulation. 1996年94卷7期1613-21页
Currently available antiarrhythmic drugs have limited efficacy for acute termination of atrial fibrillation and flutter, especially if the arrhythmia is not of recent onset. The purpose of this multicenter study was to determine the efficacy and safety of repeated doses of intravenous ibutilide, a class III antiarrhythmic drug, in terminating atrial fibrillation or flutter.
4591. Influence of dofetilide on QT-interval duration and dispersion at various heart rates during exercise in humans.
作者: J L Démolis.;C Funck-Brentano.;J Ropers.;M Ghadanfar.;D J Nichols.;P Jaillon.
来源: Circulation. 1996年94卷7期1592-9页
The objective of this study was to assess the influence of heart rate on QT-interval duration and dispersion during administration of the new selective potassium-channel blocker dofetilide in normal subjects.
4592. Circulatory status and response to cardiac rehabilitation in patients with heart failure.
We recently reported that some patients with heart failure and exercise intolerance exhibit severe hemodynamic dysfunction during exercise, whereas others have normal cardiac output responses to exercise. We postulated that patients with preserved cardiac output responses to exercise are limited by deconditioning and would respond to exercise training, whereas patients with reduced cardiac output responses are limited by skeletal muscle underperfusion and would not improve with exercise training. The present study was undertaken to test this hypothesis.
4593. Fish oils and low-molecular-weight heparin for the reduction of restenosis after percutaneous transluminal coronary angioplasty. The EMPAR Study.
作者: J A Cairns.;J Gill.;B Morton.;R Roberts.;M Gent.;J Hirsh.;D Holder.;K Finnie.;J F Marquis.;S Naqvi.;E Cohen.
来源: Circulation. 1996年94卷7期1553-60页
Percutaneous transluminal coronary angioplasty (PTCA) is complicated by restenosis within 6 months in > 40% of patients. Theoretical, animal experimental, and human epidemiological and clinical trial findings have suggested that fish oils (n-3) might reduce restenosis. Low-molecular-weight heparin (LMWH) has reduced cellular proliferation and restenosis in several experimental systems.
4594. Asymptomatic Cardiac Ischemia Pilot (ACIP) Study. Relationship between exercise-induced and ambulatory ischemia in patients with stable coronary disease.
作者: P H Stone.;B R Chaitman.;R P McMahon.;T C Andrews.;G MacCallum.;B Sharaf.;W Frishman.;J E Deanfield.;G Sopko.;C Pratt.;A D Goldberg.;W J Rogers.;J Hill.;M Proschan.;C J Pepine.;M G Bourassa.;C R Conti.
来源: Circulation. 1996年94卷7期1537-44页
We investigated whether the presence and frequency of asymptomatic ischemic episodes recorded during ambulatory ECG (AECG) monitoring could be predicted on the basis of clinical characteristics or exercise treadmill test (ETT) performance in patients with stable coronary disease and whether the estimate of ischemia severity was similar between the AECG and ETT.
4595. Intracoronary stent implantation without ultrasound guidance and with replacement of conventional anticoagulation by antiplatelet therapy. 30-day clinical outcome of the French Multicenter Registry.
作者: G J Karrillon.;M C Morice.;E Benveniste.;P Bunouf.;P Aubry.;S Cattan.;B Chevalier.;P Commeau.;A Cribier.;C Eiferman.;G Grollier.;Y Guerin.;M Henry.;T Lefevre.;B Livarek.;Y Louvard.;J Marco.;S Makowski.;J P Monassier.;J M Pernes.;P Rioux.;C Spaulding.;G Zemour.
来源: Circulation. 1996年94卷7期1519-27页
Stenting reduces both acute complications of coronary angioplasty and restenosis rates but increases subacute thrombosis rates and hemorrhagic complications when used with coumadin anticoagulation.
4596. Reduction of transient myocardial ischemia with pravastatin in addition to the conventional treatment in patients with angina pectoris. REGRESS Study Group.
作者: A J van Boven.;J W Jukema.;A H Zwinderman.;H J Crijns.;K I Lie.;A V Bruschke.
来源: Circulation. 1996年94卷7期1503-5页
Lipid-lowering therapy reduces cardiac morbidity and mortality. Less is known about its potential anti-ischemic effect.
4597. Prospective randomized trial of low-saturated-fat, low-cholesterol diet during the first 3 years of life. The STRIP baby project.
作者: H Niinikoski.;J Viikari.;T Rönnemaa.;H Lapinleimu.;E Jokinen.;P Salo.;R Seppänen.;A Leino.;J Tuominen.;I Välimäki.;O Simell.
来源: Circulation. 1996年94卷6期1386-93页
The long-term consequences of modified fat intake in early childhood are poorly known. The randomized prospective STRIP baby project evaluates the effects of repeated dietary counseling on nutrient intakes and serum lipid values in children 7 months to 3 years old.
4598. Placebo-controlled, randomized, double-blind study of intravenous enalaprilat efficacy and safety in acute cardiogenic pulmonary edema.
作者: D Annane.;E Bellissant.;E Pussard.;R Asmar.;F Lacombe.;E Lanata.;O Madonna.;M Safar.;J F Giudicelli.;P Gajdos.
来源: Circulation. 1996年94卷6期1316-24页
Converting enzyme inhibitors meet most of the criteria required to be used in acute pulmonary edema. However, they could also induce deleterious effects on renal function and electrolytes. The purpose of this study was to evaluate the efficacy and safety of a single intravenous 2-hour infusion of enalaprilat (1 mg) after an acute pulmonary edema.
4599. One-year results from the Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries (GUSTO-I) trial. GUSTO-I Investigators.
作者: R M Califf.;H D White.;F Van de Werf.;Z Sadowski.;P W Armstrong.;A Vahanian.;M L Simoons.;R J Simes.;K L Lee.;E J Topol.
来源: Circulation. 1996年94卷6期1233-8页
In the randomized Global Utilization of t-PA and Streptokinase for Occluded Coronary Arteries (GUSTO-I) trial, 41021 patients received one of four thrombolytic regimens. Patients treated with accelerated tissue plasminogen activator (TPA) had a lower 30-day mortality rate (6.3%) than those treated with the other regimens (7.3%, combined streptokinase groups).
4600. Effects of A1 adenosine receptor agonism using N6-cyclohexyl-2'-O-methyladenosine in patients with left ventricular dysfunction.
作者: B D Bertolet.;I S Anand.;R J Bryg.;P K Mohanty.;K Chatterjee.;J N Cohn.;N S Khurmi.;C J Pepine.
来源: Circulation. 1996年94卷6期1212-5页
The role of adenosine as a neuromodulator in heart failure was studied with the use of a selective adenosine A1 receptor agonist, N6-cyclohexyl-2'-O-methyladenosine (SDZ-WAG 994).
|